Raymond James Financial Inc. acquired a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 171,053 shares of the medical research company's stock, valued at approximately $9,611,000. Raymond James Financial Inc. owned about 0.09% of Exact Sciences at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in EXAS. Groupama Asset Managment bought a new stake in shares of Exact Sciences during the third quarter worth approximately $821,000. ArrowMark Colorado Holdings LLC acquired a new stake in Exact Sciences during the 3rd quarter worth $28,608,000. Iron Triangle Partners LP bought a new stake in shares of Exact Sciences during the 3rd quarter valued at $27,239,000. Erste Asset Management GmbH acquired a new position in shares of Exact Sciences in the 3rd quarter valued at $26,546,000. Finally, Bellevue Group AG boosted its position in shares of Exact Sciences by 25.1% in the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock worth $98,738,000 after purchasing an additional 290,585 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.
Exact Sciences Stock Down 3.0 %
Shares of EXAS traded down $1.42 during mid-day trading on Tuesday, hitting $45.67. 1,521,759 shares of the company's stock were exchanged, compared to its average volume of 2,615,304. The company has a 50-day simple moving average of $50.32 and a 200 day simple moving average of $58.18. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The company has a market cap of $8.48 billion, a PE ratio of -8.20 and a beta of 1.25. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. On average, research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on EXAS. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Barclays lowered their price target on Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Benchmark reissued a "buy" rating and set a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. TD Cowen upped their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Piper Sandler reduced their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, Exact Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.83.
Check Out Our Latest Stock Analysis on EXAS
Exact Sciences Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
